We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Multi-Pathogen Test Screens for In-Hospital Sepsis

By Labmedica staff writers
Posted on 05 Aug 2008
A new, fast-acting diagnostic technique has been launched to simultaneously verify a complex range of targets that indicate sepsis, the leading cause of death in non-coronary intensive care units worldwide.

Diagnosis of sepsis needs to be made during the first days of the disease. More...
Currently, physicians and clinicians choose among several tests with little confidence that the results will identify whether a patient is suffering from sepsis. Alternatively, they can order a multiple-phase blood culture test covering a range of specific targets. This is an expensive process requiring time for a disease that causes rapid deterioration in the patient's condition.

The new diagnostic technique was developed by Seegene (Seoul, Korea) and it is called the Seeplex sepsis multi-pathogen screening test. The test simultaneously screens for 64 sepsis-causing pathogens: 48 Gram-positive bacteria, 10 Gram-negative bacteria, and 6 fungi. Additionally, four drug-resistant genes: vancomycin resistant vanA and vanB; methicillin-resistant mecA; and blaSHV, a plasmid borne gene for Klebsiella pneumoniae, can be discriminated. The Seeplex Sepsis test requires only 0.4 ml of a patient's whole blood and provides test results in five hours.

The Seeplex system is a multiplexing polymerase chain reaction (PCR) technology that enables simultaneous multi-pathogen detection. Seegene applies its Seeplex system utilizing dual priming oligo (DPO) technology to create multi-pathogen tests delivering maximum specificity, reproducibility, and sensitivity. Seeplex can be applied to a broad range of molecular diagnostics.

In a recent clinical study in Korea, the Seeplex testing approach demonstrated higher sensitivity than the blood culture test-methodology. Out of 370 hospital patients suspected of having sepsis, 53 patients tested positive using the Seeplex Sepsis test while 32 patients tested positive using the blood culture method. In addition, the Seeplex test identified those higher rates of infection on the same day that blood samples were taken whereas blood cultures took three to four days.

"The Seeplex Sepsis DNA test is a fundamental breakthrough for accurate, rapid, and cost-effective sepsis diagnostics,” said Jong-Yoon Chun, CEO of Seegene. "We believe the Seeplex testing system opens a new window for not only saving lives but also furthering understanding of this complex disease by providing precise information of infected pathogens at the earliest possible stage.”


Related Links:
Seegene

Gold Member
Ketosis and DKA Test
D-3-Hydroxybutyrate (Ranbut) Assay
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Automatic CLIA Analyzer
Shine i9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Residual leukemia cells may predict long-term survival in acute myeloid leukemia (Photo courtesy of Shutterstock)

MRD Tests Could Predict Survival in Leukemia Patients

Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.